Search Results - "SIMMONS, Heidi H"

A single treatment of yttrium-90-labeled CHX-A-c6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice by ADAMS, Gregory P, SHALLER, Calvin C, DADACHOVA, Ekaterina, SIMMONS, Heidi H, HORAK, Eva M, TESFAYE, Abohawariat, KLEIN-SZANTO, Andres J. P, MARKS, James D, BRECHBIEL, Martin W, WEINER, Louis M

“…Antitumor diabody molecules are noncovalent single-chain Fv dimers that recapitulate the divalent binding properties of native IgG antibodies. Diabodies are…”
Get full text

Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer by Yuan, Qing-an, Simmons, Heidi H, Robinson, Matthew K, Russeva, Maria, Marasco, Wayne A, Adams, Gregory P

“…The Müllerian inhibiting substance type II receptor (MISIIR) is involved in Müllerian duct regression as part of the development of the male reproductive…”
Get full text

Increasing the Affinity for Tumor Antigen Enhances Bispecific Antibody Cytotoxicity by McCall, Adrian M, Shahied, Lillian, Amoroso, Anne R, Horak, Eva M, Simmons, Heidi H, Nielson, Ulrick, Adams, Gregory P, Schier, Robert, Marks, James D, Weiner, Louis M

“…We tested the hypothesis that bispecific Abs (Bsab) with increased binding affinity for tumor Ags augment retargeted antitumor cytotoxicity. We report that an…”
Get full text

High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules by ADAMS, Gregory P, SCHIER, Robert, MCCALL, Adrian M, SIMMONS, Heidi H, HORAK, Eva M, ALPAUGH, R. Katherine, MARKS, James D, WEINER, Louis M

“…Antitumor monoclonal antibodies must bind to tumor antigens with high affinity to achieve durable tumor retention. This has spurred efforts to generate high…”
Get full text

Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning by Yuan, Qing-An, Robinson, Matthew K., Simmons, Heidi H., Russeva, Maria, Adams, Gregory P.

“…While cell surface antigens represent the most common targets for antibody-based cancer therapy, isolation of new antibodies specific for these targets from…”
Get full text

Isolation of scFvs to in vitro produced extracellular domains of EGFR family members by Horak, Eva, Heitner, Tara, Robinson, Matthew K, Simmons, Heidi H, Garrison, Jennifer, Russeva, Maria, Furmanova, Polina, Lou, Jianlong, Zhou, Yu, Yuan, Qing-An, Weiner, Louis M, Adams, Gregory P, Marks, James D

“…The members of the epidermal growth factor receptor (EGFR) family are over expressed in a variety of malignancies and are frequently linked to aggressive…”
Get more information

Abstract 2437: Engineered human monoclonal antibodies targeting the Müllerian inhibiting substance type II receptor for ovarian cancer therapy by Karakasheva, Tatiana A., Simmons, Heidi H., Rudnick, Stephen I., Robinson, Matthew K., Adams, Gregory P.

“…Abstract Currently available approaches for ovarian cancer therapy have limited success in the setting of advanced disease. Antibody-based therapeutics offer…”
Get full text

Abstract 2580: Single-chain antibody based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor effects by Cao, Yu, Marks, James D., Hittelman, Walter N., Adams, Gregory P., Simmons, Heidi H., Cheung, Lawrence H., Rosenblum, Michael G.

“…Abstract Recombinant immunotoxins, consisting of single-chain antibodies (scFv) genetically fused to polypeptide toxins represent potentially effective…”
Get full text

Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer by Yuan, Qing-an, Simmons, Heidi H., Robinson, Matthew K., Russeva, Maria, Marasco, Wayne A., Adams, Gregory P.

“…Abstract The Müllerian inhibiting substance type II receptor (MISIIR) is involved in Müllerian duct regression as part of the development of the male…”
Get full text

Development of engineered antibodies specific for the Muellerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer by Yuan, Qing-an, Simmons, Heidi H, Robinson, Matthew K, Russeva, Maria, Marasco, Wayne A, Adams, Gregory P

“…The Muellerian inhibiting substance type II receptor (MISIIR) is involved in Muellerian duct regression as part of the development of the male reproductive…”
Get full text